AstraZeneca will launch Sodium Zirconium Cyclosilicate powder for oral suspension 5g (Lokelma) in India in November 2025. Lokelma is indicated for the treatment of hyperkalaemia in adult patients.

The company had earlier, on March 6, 2025, received Import and Marketing Permission (Form CT-20) from the Drugs Controller General of India (DCGI) for both the 5g and 10g strengths of Lokelma.

Earlier this month, AstraZeneca India received approval from the Central Drugs Standard Control Organisation (CDSCO) to import, market, and distribute Trastuzumab Deruxtecan (100mg/5mL vial) for an additional indication in the country.

Following the approval, Trastuzumab Deruxtecan is now indicated for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumours who have received prior systemic therapy and have no satisfactory alternative treatment options. This makes it the first and only antibody-drug conjugate (ADC) in India with a tumour-agnostic indication, marking a major milestone in precision oncology.

Trastuzumab Deruxtecan has already been approved in India for the treatment of metastatic breast cancer (HER2-positive, HER2-low, and HER2-ultralow) and locally advanced or metastatic gastric cancer. The tumour-agnostic approval further broadens its potential to benefit patients across a range of advanced HER2-positive cancers.

Headquartered in Bengaluru, Karnataka, AstraZeneca India is a subsidiary of AstraZeneca Plc, UK, and employs over 600 people across the country.